Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy

Qureshi, G. Ali; Qureshi, Ambrina; Memon, Shahabuddin; Parvez, S.

doi:10.1007/978-3-211-33328-0_24

Cited by 57 publications

(39 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 -employed blood donors. In Qureshi et al (2005Qureshi et al ( , 2006 control individuals, simply defined "healthy", were affected by tension headache, ischemic cerebrovascular disease or polyneuropathy. The Spanish group selected "healthy" subjects with suspected subarachnoid hemorrhage or pseudotumor cerebri, oculomotor palsies, etc.…”

Section: Considerations On Factors Influencing the Resultsmentioning

confidence: 99%

“…Gazzaniga et al (1992), confronting long-term levodopa treated and untreated patients, did not find any significant differences in the amounts of Cu, Fe and Mn. Qureshi et al (2005Qureshi et al ( , 2006 determined the amounts of Cu, Fe, Se and Zn in patients treated with levodopa, who were divided into two groups (PD On and PD On/Off), depending on the positive or negative response to the therapy. Fe and Se were found to be markedly higher than in controls in both kinds of patients; Zn resulted instead significantly reduced in both groups.…”

Section: Considerations On Factors Influencing the Resultsmentioning

confidence: 99%

“…Aguilar et al (1998) found for PD subjects a non significant selenium increment -see Tab. 7; a significant elevation resulted instead in all the patients, with both positive and negative response to the therapy, enrolled by Qureshi et al (2006). Lead -see Tab.…”

Section: Summary Of the Retrieved Datamentioning

confidence: 96%

See 2 more Smart Citations

Minor and Trace Elements in Cerebrospinal Fluid of Parkinson's Patients – Suggestions After a Critical Review of the Analytical Data

Speziali¹,

Casa²

2011

Diagnostics and Rehabilitation of Parkinson's Disease

View full text Add to dashboard Cite

Section: Considerations On Factors Influencing the Resultsmentioning

confidence: 99%

Section: Considerations On Factors Influencing the Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Minor and Trace Elements in Cerebrospinal Fluid of Parkinson's Patients – Suggestions After a Critical Review of the Analytical Data

Speziali¹,

Casa²

2011

Diagnostics and Rehabilitation of Parkinson's Disease

View full text Add to dashboard Cite

“…However, information is a bit mixed concerning Fe level in plasma/serum of PD patients, which showed all directions of changes from a decrease [16,23], to no change [10,24,25], and to an increase [26]. In the present study, we found plasma Fe level was only elevated in younger (age ≤55) PD patients and decreased ever since, which somewhat explains the dissimilarity of plasma/serum Fe levels in previous reports when only recruiting limited sample size.…”

Section: Discussionmentioning

confidence: 99%

Assessing Plasma Levels of Selenium, Copper, Iron and Zinc in Patients of Parkinson’s Disease

et al. 2013

View full text Add to dashboard Cite

Trace elements have been recognized to play an important role in the development of Parkinson’s disease (PD). However, it is difficult to precisely identify the relationship between these elements and the progression of PD because of an insufficient number of patients. In this study, quantifications of selenium (Se), copper (Cu), iron (Fe) and zinc (Zn) by atomic absorption spectrophotometry were performed in plasma from 238 PD patients and 302 controls recruited from eastern China, which is so far the largest cohort of PD patients and controls for measuring plasma levels of these elements. We found that plasma Se and Fe concentrations were significantly increased whereas Cu and Zn concentrations decreased in PD patients as compared with controls. Meanwhile, these four elements displayed differential changes with regard to age. Linear and logistic regression analyses revealed that both Fe and Zn were negatively correlated with age in PD patients. Association analysis suggests that lower plasma Se and Fe levels may reduce the risk for PD, whereas lower plasma Zn is probably a PD risk factor. Finally, a model was generated to predict PD patients based on the plasma concentrations of these four trace elements as well as other features such as sex and age, which achieved an accuracy of 80.97±1.34% using 10-fold cross-validation. In summary, our data provide new insights into the roles of Se, Cu, Fe and Zn in PD progression.

show abstract

“…In particular, since the first discovery in 1955, Zn 2+ has been known to be highly enriched in the hippocampus [2] and neocortical (150 – 200 µM [3, 4]) region of the mammalian brain [5]. Zn 2+ is necessary for the maturation and function of the brain and a dysregulation of brain Zn 2+ -levels is seen in many psychiatric and neurological diseases like Parkinson’s [6–8] and Alzheimer’s disease [6, 9–11], schizophrenia [12, 13], ADHD [14–16], mood disorders [17–20], amyotrophic lateral sclerosis (ALS) [21], Down's syndrome [22], multiple sclerosis [23, 24], epilepsy [25–27], Wilson’s disease [28, 29] and Pick’s disease [30]. …”

Section: Introductionmentioning

confidence: 99%

Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review

Grabrucker¹,

Rowan²,

Garner³

2011

DDL

View full text Add to dashboard Cite

Homeostasis of metal ions such as Zn2+ is essential for proper brain function. Moreover, the list of psychiatric and neurodegenerative disorders involving a dysregulation of brain Zn2+-levels is long and steadily growing, including Parkinson’s and Alzheimer’s disease as well as schizophrenia, attention deficit and hyperactivity disorder, depression, amyotrophic lateral sclerosis, Down's syndrome, multiple sclerosis, Wilson’s disease and Pick’s disease. Furthermore, alterations in Zn2+-levels are seen in transient forebrain ischemia, seizures, traumatic brain injury and alcoholism. Thus, the possibility of altering Zn2+-levels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. Although the role of Zn2+ in the brain has been extensively studied over the past decades, methods for controlled regulation and manipulation of Zn2+ concentrations within the brain are still in their infancy. Since the use of dietary Zn2+ supplementation and restriction has major limitations, new methods and alternative approaches are currently under investigation, such as the use of intracranial infusion of Zn2+ chelators or nanoparticle technologies to elevate or decrease intracellular Zn2+ levels. Therefore, this review briefly summarizes the role of Zn2+ in psychiatric and neurodegenerative diseases and highlights key findings and impediments of brain Zn2+-level manipulation. Furthermore, some methods and compounds, such as metal ion chelation, redistribution and supplementation that are used to control brain Zn2+-levels in order to treat brain disorders are evaluated.

show abstract

Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy

Cited by 57 publications

References 35 publications

Minor and Trace Elements in Cerebrospinal Fluid of Parkinson's Patients – Suggestions After a Critical Review of the Analytical Data

Minor and Trace Elements in Cerebrospinal Fluid of Parkinson's Patients – Suggestions After a Critical Review of the Analytical Data

Assessing Plasma Levels of Selenium, Copper, Iron and Zinc in Patients of Parkinson’s Disease

Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review

Contact Info

Product

Resources

About